EUCTR2019-004169-42-SK进行中（未招募）1 期
Randomized, double-blind, parallel group, Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory and/orunexplained chronic cough (RUCC) - PAGANINI
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Bayer AG
- 入组人数
- 236
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Adults = 18 years of age at the time of signing the informed consent.
- •2. A cough that has lasted for at least 12 months (unresponsive to treatment options) with a diagnosis of refractory chronic cough and/or idiopathic (unexplained) chronic cough.
- •3. Persistent cough for at least the last 8 weeks before screening.
- •4. Women of childbearing potential must agree to use acceptable effective or highly effective birth control methods during the study and for at least 30 days after the last dose.
- •5. Capable of giving signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 136
排除标准
- •1. Smoking history within the last 12 months before screening (all forms
- •of smoking, including e-cigarettes, cannabis and others), and any former
- •smoker with more than 20 pack-years.
- •2. Ongoing or previous exposure to inhalational toxic fumes (e.g.,
- •ammonia, chlorine, nitrogen dioxide, phosgene and sulfur dioxide)
- •within the last 12 months before screening.
- •3. Respiratory tract infection within 4 weeks before screening.
- •4. History of chronic bronchitis.
- •5. Systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 100 mmHg at screening visit.
- •6. Positive SARS-CoV-2 virus RNA and/or serology IgG tests at screening visit.
研究者
相似试验
进行中（未招募）
1 期
Clinical study to evaluate the efficacy and safety of three different doses of BAY 1817080 compared to placebo in patients with chronic coughRefractory and/or unexplained chronic cough (RUCC)MedDRA version: 21.0Level: LLTClassification code 10080782Term: Refractory chronic coughSystem Organ Class: 100000004855MedDRA version: 21.0Level: LLTClassification code 10080781Term: Unexplained chronic coughSystem Organ Class: 100000004855EUCTR2019-004169-42-PLBayer AG236
进行中（未招募）
1 期
Clinical study to evaluate the efficacy and safety of three different doses of BAY 1817080 compared to placebo in patients with chronic coughEUCTR2019-004169-42-FRBayer AG236
进行中（未招募）
1 期
Clinical study to evaluate the efficacy and safety of three different doses of BAY 1817080 compared to placebo in patients with chronic coughRefractory and/or unexplained chronic cough (RUCC)MedDRA version: 21.0Level: LLTClassification code 10080782Term: Refractory chronic coughSystem Organ Class: 100000004855MedDRA version: 21.0Level: LLTClassification code 10080781Term: Unexplained chronic coughSystem Organ Class: 100000004855EUCTR2019-004169-42-ITBayer AG236
已完成
2 期
Randomized, double-blind, parallel group, Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory and/or unexplained chronic cough (RUCC)NL-OMON50167Bayer8
进行中（未招募）
1 期
Clinical study to evaluate the efficacy and safety of three different doses of BAY 1817080 compared to placebo in patients with chronic coughRefractory and/or unexplained chronic cough (RUCC)MedDRA version: 21.0Level: LLTClassification code 10080782Term: Refractory chronic coughSystem Organ Class: 100000004855MedDRA version: 21.0Level: LLTClassification code 10080781Term: Unexplained chronic coughSystem Organ Class: 100000004855EUCTR2019-004169-42-DEBayer AG310